Since the discovery of c-myb as a cellular homologue of the v-myb oncogene transduced by AMV or E26 (Baluda and Reddy, 1994) , two additional members of the myb gene family have been identified and termed as A-myb and B-myb (Nomura et al., 1988; Oh and Reddy, 1999) . These genes encode the nuclear transcription factors (Biedenkapp et al., 1988; Weston and Bishop, 1989 ) that exhibit a modular structure with a high degree of homology in the tryptophan-rich N-terminal DNA binding domain (Saikumar et al., 1990) , the central transactivation domain and, albeit to a lesser extent, the C-terminal domain (Kalkbrenner et al., 1990; Mettus et al., 1994) (Figure 1a) .
Despite the high degree of structural homology, the biochemical, cellular and developmental events that are regulated by these proteins are significantly different. The transactivational activity exhibited by each Myb protein induces a unique pattern of gene expression (Rushton et al., 2003) and targeted disruption of each gene causes distinct abnormalities during the developmental process (Mucenski et al., 1991; Toscani et al., 1997; Tanaka et al., 1999) . While the differences in the biochemical function of each Myb protein are not yet clear, the transactivation activity of each protein appears to be differentially regulated. For example, the Cterminal domains of A-Myb and c-Myb have been described as negative regulatory domains since deletion of these regions results in an increase in their transactivation potential (Sakura et al., 1989; Weston and Bishop, 1989; Oh and Reddy, 1997) . In contrast, the C-terminus of B-Myb has a positive regulatory function (Oh and Reddy, 1998) , since deletion of this region leads to a significant loss of the protein's transactivational activity. Additionally, use of the 32Dcl3 cell model system has shown that overexpression of these myb genes resulted in different phenotypes, that is, ectopic overexpression of cmyb blocked their terminal differentiation into granulocytes (Bies et al., 1995; Patel et al., 1996) , while ectopic overexpression of either A-myb or B-myb failed to induce such a block Reddy, 1997, 1998) .
These observations suggest that Myb proteins might exert their distinctive transactivation effects through differential interactions with other nuclear factors. Furthermore, the differences observed in the transactivation properties of the different Myb proteins are highly dependent on the nature of the cell lines used in the assays, again suggesting that other transcription factors that cooperate with Myb proteins play a critical role in their biochemical and biological functions (Oh and Reddy, 1999) . In accordance, the transactivation potential of c-Myb appears to be regulated by interactions with other nuclear transcription factors (Dai et al., 1996; Dash et al., 1996) . One such interaction is with another oncoprotein, Ets-2 (Dudek et al., 1992) , where transactivation by c-Myb was greatly increased by co-expression with Ets-2. However, the mechanisms of functional domains that are responsible for this transcriptional cooperation are not yet clear. Furthermore, it remains unknown whether a difference exists in the ability of other Myb proteins to cooperate with Ets-2, which would constitute another level of regulation and distinction among members of this family.
To answer these questions, we performed transactivation studies to compare the ability of each myb gene product to cooperate with Ets proteins and to identify the domains involved in the transactivational cooperation. First, the ability of each wild-type Myb protein to cooperate with Ets-2 was compared by cotransfecting expression plasmids encoding a myb gene, ets-1 or ets-2, and a reporter gene. As shown in Figure 1b , the three myb genes were expressed under the control of the CMV promoter, while the expression of ets-1 or ets-2 was driven by the SV-40 promoter to minimize possible promoter interference. The pTA-luc plasmid contains three copies of the Myb binding site upstream of the thymidine kinase promoter and was used as a reporter because the transactivation properties of each of the myb gene products have been well characterized previously (Ness et al., 1989) . As shown in Figure 1c , transfection of the reporter and c-myb expression plasmids resulted in an approximate 10-fold increase in the transactivation of the reporter construct as compared to the vector controls, whereas transfection of the ets-1 or ets-2 expression vector along with the reporter construct in the absence of c-myb did not result in any significant transactivation of the reporter gene. However, co-transfection of the c-myb with the ets-2 expression plasmid, but not ets-1, resulted in an approximate 35-fold increase in the level of transactivation of the reporter gene, confirming the earlier observation that Ets-2, but not Ets-1, can cooperate with c-Myb (Dudek et al., 1992) . Similar to that observed with c-Myb, transfection of the A-myb expression vector along with the reporter construct resulted in an approximate 3.5-fold increase in transactivation. Moreover, co-expression of A-myb with ets-2 resulted in an approximate 25-fold increase in transactivation, but this increase was not observed upon cotransfection with ets-1. In contrast, co-transfection of the B-myb expression plasmid with that of ets-2 or ets-1 did not change the transactivation activity of B-Myb. These results show that functional differences in myb gene products exist with respect to their ability to cooperate with Ets-2 and that the activity of myb gene products can be differentially regulated by Ets-2.
As only those myb genes that are negatively regulated in-cis by their C-termini (i.e. A-Myb and C-Myb, but not B-Myb) exhibited transcriptional cooperation with Ets-2, it could be speculated that the increase in transactivation caused by Ets-2 might require the presence of the negative regulatory domain in such a way that Ets-2 represses the negative regulatory function of the C-termini of A-Myb and C-Myb. In order to test this possibility, truncated mutants of A-Myb and c-Myb (Figure 2a) , where their C-terminal negative regulatory domains were deleted, were tested for their ability to cooperate with Ets-2. Surprisingly, when these truncated mutants (tr.-CC or tr.-AA) were co-expressed with ets-2, they showed similar abilities to cooperate with Ets-2 as their wild-type counterparts (Figure 2b ). These results suggest that Ets-2 can directly cooperate with the Nterminal DNA binding and/or transactivation domains of A-Myb and C-Myb. These results also suggest that the C-terminal domains of these two proteins do not play a significant role in Ets-2 cooperation.
We next sought to determine the mechanism that is responsible for the lack of transcriptional cooperation between B-Myb with Ets-2. As the DNA binding and transactivation domains of B-Myb show high homology to c-Myb (90% and 60% each, respectively), we examined the transactivation potential of a truncated B-Myb mutant (trunc-BB) that has no C-terminal regulatory domain ( Figure 3a ). As shown in Figure 3b , deletion of the C-terminus of B-Myb resulted in a sharp decrease in its transactivation potential, consistent with the finding that the C-terminal region of B-Myb acts as a positive regulator of B-Myb transactivation activity (Nakagoshi et al., 1993; Watson et al., 1993; Oh and Reddy, 1998) . Surprisingly, when the truncated B-myb mutant was co-transfected with ets-2, a four-fold increase in the transactivation potential was observed, demonstrating that this protein (trunc-BB) had the ability to cooperate with Ets-2. However, the B-myb mutant with a deletion in the transactivation domain (dl-B-myb) did not cooperate with Ets-2, supporting the notion that the transactivation domain is involved in Ets-2 cooperation. Taken together, these results suggest that the DNA binding and transactivation domains of B-Myb have an intrinsic ability to cooperate with Ets-2, although this phenomenon is blocked by the presence of the C-terminal positive regulatory domain. In order to confirm these observations, a series of chimeric genes, where the three functional domains of c-myb and B-myb have been exchanged, were tested for their ability to cooperate with Ets-2 (Figure 3a ) (Oh and Reddy, 1998) . As shown in Figure 3b , the Chimera CBC, which contains the DNA binding and negative regulatory domains of c-Myb but the transactivation domain of B-Myb, showed an approximate four-fold increase in the level of transactivation compared to that of the control. The decreased transactivation potential of this chimera might be due to the presence of the weak transactivation domain of B-Myb and the absence of the positive regulatory C-terminus. However, co-transfection of this chimera with ets-2 resulted in roughly a 12-fold enhancement in the level of transactivation, which is a three-fold increase with respect to the chimeric gene alone. Similarly, chimeras BBC and BCC, which contain the C-terminal domain of c-Myb, , and each open box represents the domain derived from c-Myb, marked as 'C'. The structural integrity and expression of these constructs were previously confirmed (Oh and Reddy, 1998) . (b) Transcriptional cooperation of the chimeric proteins and Ets-2. Transcriptional cooperation between the constructs shown in (a) and Ets-2 was examined by co-transfection as described above in Figure 1c . The values shown are the mean fold activation obtained from at least three independent experiments, with vertical bars representing the standard deviations showed a two-to three-fold increase in the level of transactivation when co-transfected with ets-2. These findings further support the hypothesis that the DNA binding domain or the transactivation domain of B-Myb can cooperate with Ets-2, and that the presence of the c-Myb C-terminus permits transcriptional cooperation with Ets-2.
The chimeras containing the C-terminal positive regulatory domain of B-Myb (chimeras CCB and CBB) were next examined for their ability to cooperate with Ets-2. These chimeras exhibited a transactivation potential of approximately 20-to 25-fold above the control, suggesting that the B-Myb C-terminus can also exert a positive regulatory function. However, no significant increase in transactivation was observed when these constructs were co-transfected with ets-2. The lack of an increase in transactivation does not appear to be due to a saturation of the transcription factors, because fold activation obtained with t-Myb, which is c-myb with a truncated C-terminus, reached up to 67-fold in the same experiment (data not shown). Taken together, these results show that chimeric genes that contain the C-terminus of B-Myb do not cooperate with Ets-2, suggesting that this region blocks transcriptional cooperation of wild-type B-Myb with Ets-2.
In summary, our results show that myb family gene products behave differently with respect to their ability to transactivate and cooperate with Ets-2. While transactivation by A-Myb or c-Myb is under the negative regulatory control of their C-terminal domains in-cis, this activity can be upregulated by transcriptional cooperation in-trans with Ets-2, converting these proteins into much stronger transactivating molecules. On the other hand, B-Myb transactivation is positively regulated by its C-terminal positive regulatory domain. However, enhanced transactivational activity that is induced as a result of cooperation with Ets-2 is blocked by this same domain, thus making the transactivation potential of B-Myb independent of Ets-2. Although the significance of Ets-2 cooperation remains unknown, it has been shown that Ets proteins are phosphorylated in response to growth factor signals (Pognonec et al., 1988; Fujiwara et al., 1990) , which raises the possibility that Myb-Ets cooperation could constitute another mechanism by which myb genes are regulated by extracellular signals.
At present, the molecular mechanisms that are responsible for the differential Myb-Ets cooperation remain unknown. Interestingly, the C-terminal domain of c-Myb was shown to contain a motif (EVES/AVES) that mediates the interaction of this domain with the Nterminal DNA binding domain, thereby resulting in an intramolecular folding and negative autoregulation (Dash et al., 1996) . In addition, our study shows that truncated mutants that contain only the DNA binding and transactivation domains of each of the three myb genes were sufficient to cooperate with Ets-2. Based on these findings, we suggest a model (illustrated in Figure 4 ) wherein the C-termini of the three myb genes exist in distinct conformations with respect to their positive or negative regulatory roles. According to our model, the C-terminus of A-Myb or C-Myb exists in a conformation that promotes cooperation with Ets-2. However, the B-Myb C-terminus assumes a conformation that simultaneously exerts a positive effect on the transactivation domain and prevents cooperation with Ets-2. Further studies on the mechanisms and functional outcomes of Myb-Ets cooperation are warranted to elucidate the significance of the differential modulation of the myb family genes by ets-2. 
